QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

TEVATICKER

Teva Pharmaceutical Industries Ltd.

NEUTRAL stock

Congress has disclosed 5 buys and 11 sells of TEVA (Teva Pharmaceutical Industries Ltd.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

5
Buy
11
Sell
-6
Net
8
Active politicians

Round-trip watch Still on the books

Members who disclosed buying TEVA and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Alan Armstrong 2026-03-30 $28.35 $41.54 +46.5% in profit

Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
95.78
▲ pricier than Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$41.54 ÷ $0.43 = 95.78
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
6.07
▲ pricier than Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$41.54 ÷ $6.84 = 6.07
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
19.87
▲ pricier than Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($48.5B − $0.0B net cash) ÷ $2.4B = $48.4B ÷ $2.4B = 19.87
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

Legislation Related Legislation

Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

16 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Alan Armstrong Senate BUY ◆ insider divergence · moderate Self 2026-03-30 113 days +10.6% $1K–$15K 99.1 ↗ eFD
Greg Gianforte House BUY Joint 2020-11-13 3 days — $15K–$50K 90.9 ↗ filing
Donna Shalala House SELL Self 2020-05-07 0 days — $1K–$15K 75.9 ↗ filing
David Price House SELL Self 2019-06-19 5 days — $1K–$15K 75.9 ↗ filing
Cheri Bustos House SELL Self 2017-01-30 3 days — $1K–$15K 82.1 ↗ filing
Michael Conaway House SELL Spouse 2016-09-12 3 days — $1K–$15K 10.6 ↗ filing
Michael Conaway House SELL Spouse 2016-05-11 2 days — $1K–$15K 15.7 ↗ filing
Michael Conaway House SELL Spouse 2016-05-04 2 days — $1K–$15K 22.3 ↗ filing
Alan Lowenthal House SELL Spouse 2015-09-11 6 days — $15K–$50K 30.7 ↗ filing
Alan Lowenthal House SELL Spouse 2015-07-27 4 days — $15K–$50K 48.0 ↗ filing
Michael Conaway House SELL Spouse 2015-02-09 3 days — $1K–$15K 52.4 ↗ filing
Thomas MacArthur House SELL Joint 2015-01-27 5 days — $1K–$15K 52.4 ↗ filing
Thomas MacArthur House BUY Joint 2015-01-06 26 days — $1K–$15K 86.8 ↗ filing
Alan Lowenthal House BUY Spouse 2014-12-19 5 days — $15K–$50K 63.1 ↗ filing
Alan Lowenthal House BUY Spouse 2014-12-12 5 days — $15K–$50K 94.9 ↗ filing
Michael Conaway House SELL Spouse 2014-03-12 5 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in TEVA — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

0
Congress trades with insider convergence
1
…with insider divergence
135
Insider open-market trades

Of the congressional trades in TEVA, 0 coincided with corporate insiders moving the same way within 60 days, and 1 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-09-18 MIGNONE ROBERTO Director SELL $14.4M ↗ EDGAR
2026-09-18 Savage Brian C-suite SELL $174K ↗ EDGAR
2026-09-18 Savage Brian C-suite SELL $99K ↗ EDGAR
2026-09-18 Savage Brian C-suite SELL $12K ↗ EDGAR
2026-08-21 Satchi-Fainaro Ronit Director SELL $15K ↗ EDGAR
2026-08-21 Weiss Amir C-suite SELL $261K ↗ EDGAR
2026-08-21 Weiss Amir C-suite SELL $94K ↗ EDGAR
2026-08-17 Lippman Evan Other SELL 10b5-1 $680K ↗ EDGAR
2026-08-05 Zaks Tal Zvi Director SELL $593 ↗ EDGAR
2026-08-03 Hughes Eric A Other SELL 10b5-1 $892K ↗ EDGAR
2026-08-03 Jover Placid Other SELL 10b5-1 $447K ↗ EDGAR
2026-06-18 Shields Matthew Other SELL $322K ↗ EDGAR
2026-06-11 Kalif Eliyahu Sharon C-suite SELL 10b5-1 $3.6M ↗ EDGAR
2026-06-05 Francis Richard D C-suite SELL 10b5-1 $211K ↗ EDGAR
2026-06-03 Shields Matthew Other SELL 10b5-1 $532K ↗ EDGAR
2026-05-14 Kalif Eliyahu Sharon C-suite SELL 10b5-1 $5.5M ↗ EDGAR
2026-05-14 Lippman Evan Other SELL 10b5-1 $204K ↗ EDGAR
2026-05-14 Lippman Evan Other SELL 10b5-1 $1.3M ↗ EDGAR
2026-05-06 Weiss Amir C-suite SELL $384K ↗ EDGAR
2026-05-05 Daniell Richard Other SELL $1.1M ↗ EDGAR
2026-05-01 Sabag Mark Other SELL $5.0M ↗ EDGAR
2026-04-30 Fox Christine Other SELL $751K ↗ EDGAR
2026-03-17 Sabag Mark Other SELL $1.9M ↗ EDGAR
2026-03-05 Shields Matthew Other SELL 10b5-1 $548K ↗ EDGAR
2026-03-05 Savage Brian C-suite SELL $36K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-09-18 MIGNONE ROBERTO Director SELL $14.4M
◆ insider 2026-09-18 Savage Brian C-suite SELL $174K
◆ insider 2026-09-18 Savage Brian C-suite SELL $99K
◆ insider 2026-09-18 Savage Brian C-suite SELL $12K
◆ insider 2026-08-21 Satchi-Fainaro Ronit Director SELL $15K
◆ insider 2026-08-21 Weiss Amir C-suite SELL $261K
◆ insider 2026-08-21 Weiss Amir C-suite SELL $94K
◆ insider 2026-08-17 Lippman Evan Other 10b5-1 SELL $680K
◆ insider 2026-08-05 Zaks Tal Zvi Director SELL $593
◆ insider 2026-08-03 Hughes Eric A Other 10b5-1 SELL $892K
◆ insider 2026-08-03 Jover Placid Other 10b5-1 SELL $447K
◆ insider 2026-06-18 Shields Matthew Other SELL $322K
◆ insider 2026-06-11 Kalif Eliyahu Sharon C-suite 10b5-1 SELL $3.6M
◆ insider 2026-06-05 Francis Richard D C-suite 10b5-1 SELL $211K
◆ insider 2026-06-03 Shields Matthew Other 10b5-1 SELL $532K
◆ insider 2026-05-14 Kalif Eliyahu Sharon C-suite 10b5-1 SELL $5.5M
◆ insider 2026-05-14 Lippman Evan Other 10b5-1 SELL $204K
◆ insider 2026-05-14 Lippman Evan Other 10b5-1 SELL $1.3M
◆ insider 2026-05-06 Weiss Amir C-suite SELL $384K
◆ insider 2026-05-05 Daniell Richard Other SELL $1.1M
◆ insider 2026-05-01 Sabag Mark Other SELL $5.0M
◆ insider 2026-04-30 Fox Christine Other SELL $751K
Congress 2026-03-30 Alan Armstrong BUY $1K–$15K
◆ insider 2026-03-17 Sabag Mark Other SELL $1.9M

FAQ Common questions

How much has Congress traded TEVA?

5 disclosed buys and 11 sells of TEVA (Teva Pharmaceutical Industries Ltd.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade TEVA?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.